Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the C-Reactive Protein Testing Market by the end of 2030?

The c-reactive protein testing market has experienced robust growth in recent years. This market is projected to expand from $3.52 billion in 2025 to $3.7 billion in 2026, at a compound annual growth rate (CAGR) of 5.1%. Historically, this growth can be attributed to the increasing prevalence of inflammatory diseases, the rising use of crp testing in clinical diagnostics, the expansion of hospital laboratory infrastructure, growing awareness of early disease detection, and the availability of standardized assay kits.

The c-reactive protein testing market is projected to experience consistent expansion over the upcoming years, with its size anticipated to reach $4.48 billion by 2030, driven by a compound annual growth rate (CAGR) of 4.9%. This projected growth during the forecast period is primarily attributed to a heightened demand for point-of-care inflammatory testing, the increasing integration of automated diagnostics platforms, the broadening scope of preventive healthcare screening, a growing adoption of high-throughput laboratory systems, and an intensifying focus on personalized medicine diagnostics. Concurrently, major trends expected in the forecast period include the increasing adoption of high-sensitivity crp assays, a rising use of automated immunoassay systems, a growing demand for rapid inflammation diagnostics, the expansion of crp testing in cardiovascular risk assessment, and an enhanced focus on laboratory workflow automation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6719&type=smp

What Drivers Are Shaping Future Opportunities In The C-Reactive Protein Testing Market?

A rise in cases of cardiovascular diseases (CVD) is projected to propel the expansion of the c-reactive protein testing market in the coming years. Cardiovascular diseases encompass various heart conditions, including diseased vessels, structural issues, and blood clots. While the precise cause of CVD remains unknown, numerous factors can heighten the risk of its development. One such factor involves behavioral risks stemming from unbalanced eating, insufficient physical activity, smoking, and alcohol use, which lead to the accumulation of fatty deposits inside the arteries (atherosclerosis), thereby increasing the likelihood of blood clots. These behavioral risks contribute to elevated blood pressure, glucose, blood lipids, weight gain, and obesity. The increasing prevalence of cardiovascular diseases highlights the necessity for c-reactive protein testing to diagnose or predict the chance of developing cardiovascular problems at least as effectively as cholesterol levels. For instance, in October 2024, according to the Centers for Disease Control, a US-based government agency, approximately 919,032 people died from cardiovascular disease in 2023, accounting for 1 in every 3 deaths. Consequently, the growing incidence of cardiovascular diseases (CVD) is a primary driver for the C-reactive protein testing market.

Which Segments Are Gaining Traction In The C-Reactive Protein Testing Market?

The c-reactive protein testing market covered in this report is segmented –

1) By Assay Type: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays

2) By Application: Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Cancer, Other Applications

3) By End Use: Clinics, Hospitals, Diagnostic Laboratories

Subsegments:

1) By Enzyme-Linked Immunosorbent Assay (ELISA): Direct ELISA, Indirect ELISA, Sandwich ELISA

2) By Chemiluminescence Immunoassay (CLIA): Luminometer-Based CLIA, Automated CLIA Systems

3) By Immunoturbidimetric Assays: Nephelometry-Based Immunoturbidimetric Assays, Latex Agglutination Immunoturbidimetric Assays

Which Trends Are Influencing The Development Of The C-Reactive Protein Testing Market?

Leading companies in the C-reactive protein testing market are focusing on developing technological advancements, such as high-sensitivity automated immunoassays, to achieve more accurate, rapid, and low-level CRP detection. This supports early cardiovascular risk stratification and real-time inflammation monitoring. High-sensitivity automated immunoassays utilize refined immunoturbidimetric or nephelometric techniques to detect extremely low CRP levels, far below what standard CRP assays can achieve, thus enabling earlier intervention and improved prognostic evaluation. For instance, in January 2024, Siemens Healthineers, a Germany-based in vitro diagnostics company, launched the Atellica CH High Sensitivity C-Reactive Protein 2 (hCRP2) assay designed for its Atellica CH Analyzer. This product includes two ready-to-use reagent packs: one containing a phosphate buffer with surfactant, and the other holding monoclonal anti-CRP antibodies attached to polystyrene particles. When CRP in a patient sample causes these particles to aggregate, light scattering is measured, with its intensity proportional to the CRP concentration. The system excels at very low-level CRP detection for cardiovascular risk stratification, is compatible with both serum and plasma samples, and delivers swift quantitative results for timely clinical decision-making.

Who Are The Primary Competitors In The Global C-Reactive Protein Testing Market?

Major companies operating in the c-reactive protein testing market are Thermo Fisher Scientific Inc., F Hoffmann-La Roche AG, Danaher Corporation, Quest Diagnostics Incorporated, Siemens AG, Abbott Laboratories, Aidian Oy, Boditech Med Inc., Horiba Ltd., Laboratory Corporation, Merck KGAA, Randox Laboratories Limited, Getein Biotech Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., Eurofins Scientific SE, Inova Diagnostics Inc., Luminex Corporation, Sekisui Diagnostics LLC, Sysmex Corporation, Tosoh Corporation, Trinity Biotech Plc, WerfenLife Group LLC, ZEUS Scientific Inc., BioMérieux SA, Biomerica Inc., Gold Standard Diagnostics Corp., Immunodiagnostic Systems Holdings PLC, Nova Biomedical Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/c-reactive-protein-testing-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The C-Reactive Protein Testing Market?

North America was the largest region in the c-reactive protein testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized C-Reactive Protein Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6719&type=smp

Browse Through More Reports Similar to the Global C-Reactive Protein Testing Market 2026, By The Business Research Company

Packaged Salad Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/packaged-salad-global-market-report

Packaged Sunflower Seeds Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/packaged-sunflower-seeds-global-market-report

Packaged Wastewater Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/packaged-wastewater-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company